Intrinsic Imaging
Imaging core lab team beside a monitor showing an Alzheimer’s trial case: coronal MRI with hippocampal segmentation, amyloid PET/MRI fusion and a 24-month hippocampal volume chart

Imaging Core Lab Case Studies

These case studies illustrate Intrinsic Imaging’s approach to complex imaging challenges in clinical development. Each examines the sponsor’s objectives, the central review strategy and the resulting contribution to study execution.

Sponsor identities remain confidential. The studies describe work conducted within our quality management framework, supported by three FDA inspections with zero Form 483 observations and five ISO certifications.

Case Study Library

Intrinsic Imaging

Oncology

Rescuing a Global Phase III Solid Tumor Trial

  • 70+ sites
  • CT, MRI, PET/CT
  • RECIST 1.1 BICR

Challenge

Midway through a global Phase III solid tumor program, the sponsor confronted a central review process with substantial operational deficiencies. The incumbent core lab's reads were marked by substantial inter-reader disagreement, and a growing backlog of unresolved queries was compromising the reliability of the imaging dataset. Protocol adherence varied widely across more than 70 sites spanning multiple continents, compounding the inconsistency of the response assessments on which the trial's primary endpoint depended. With the NDA submission timeline already fixed, the sponsor needed a partner capable of assuming control of the program mid-study without sacrificing continuity, data integrity, or regulatory defensibility.

Read the case study
Intrinsic Imaging

Oncology

Phase III Immunotherapy RECIST and iRECIST

  • 90+ sites in 18 countries
  • CT, MRI
  • RECIST 1.1 and iRECIST

Challenge

Immunotherapy trials present a distinctive interpretive challenge: apparent radiographic progression may reflect treatment-related inflammation rather than true tumor growth. The sponsor required central reviewers to distinguish pseudoprogression from genuine disease progression with consistency across more than 90 sites in 18 countries, while applying two response frameworks—RECIST 1.1 and iRECIST—in parallel. Any variability in how unconfirmed progression was identified, confirmed, or dated threatened to distort the trial's efficacy conclusions and invite regulatory scrutiny.

Read the case study
Intrinsic Imaging

AI/CAD

MRMC Reader Study for AI 510(k) Submission

  • Multi-reader multi-case
  • Reference-standard panel
  • Part 11 reading environment

Challenge

An AI developer preparing a 510(k) submission required a pivotal multi-reader multi-case study to evaluate whether algorithmic assistance improved reader performance. The study's credibility depended in part on its reference standard: every case needed a systematically established reference determination supported by documentation suitable for FDA review. The design also had to control for recall bias and ordering effects across reading sessions, while documenting every step in a manner suitable for regulatory inspection.

Read the case study
Intrinsic Imaging

Central Nervous System

Phase II Alzheimer's Amyloid PET and MRI

  • 55 sites
  • 3T MRI, amyloid PET
  • Volumetric and visual PET endpoints

Challenge

In a Phase II Alzheimer's disease program, the trial's biomarker endpoints depended on detecting subtle changes in brain volume and amyloid burden over time. Yet the 55 participating academic and commercial imaging centers operated scanners from multiple vendors, each introducing its own measurement variability into volumetric MRI quantification and amyloid PET assessment. Without adequate control, this cross-site variability could obscure treatment-related changes and compromise interpretation of both the secondary and exploratory biomarker endpoints.

Read the case study
Intrinsic Imaging

Medical Device

IDE Pivotal Transcatheter Valve Trial

  • Structural heart
  • CT, fluoroscopy, echocardiography
  • Pre- and post-implant assessment

Challenge

A pivotal IDE trial of a transcatheter valve replacement system required standardized imaging for anatomical assessment and longitudinal evaluation of device performance. Precise anatomical sizing before the procedure was essential to device selection and patient safety, while consistent core lab review of post-implant imaging over extended follow-up was required to document device performance, positioning, and durability. Measurements taken at different timepoints and by different readers had to remain directly comparable, and every assessment needed to satisfy the evidentiary standard of a PMA submission.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

Global Cardiovascular Trial With CCTA and MRI

  • 60 sites
  • CCTA, cardiac MRI
  • Plaque, stenosis and LVEF

Challenge

This global cardiovascular outcomes trial required reproducible quantification of coronary plaque burden, stenosis grading, and left ventricular ejection fraction across 60 sites operating a heterogeneous mix of scanner models. Each measurement contributed to endpoint assessment, and even modest inter-reader or inter-site variability could obscure a potential treatment effect. The sponsor required acquisition and interpretation methods that supported measurement comparability across sites and scanner platforms, with technical limitations identified and documented throughout the program.

Read the case study
Intrinsic Imaging

Musculoskeletal

Phase III Knee Osteoarthritis DMOAD Trial

  • 24-month follow-up
  • Knee MRI, radiographs
  • JSN and WORMS

Challenge

Evaluating disease modification in knee osteoarthritis requires reproducible measurement of submillimeter changes in joint space narrowing over extended follow-up. The sponsor required readings of sufficient precision to register these minute structural changes, together with consistent tracking of WORMS scores across 24 months of serial MRI examinations. Since the primary structural endpoint rested on longitudinal comparison, any drift in reader interpretation or measurement technique over the study's duration would directly compromise the trial's conclusions.

Read the case study
Intrinsic Imaging

Gastroenterology & Metabolic

Phase IIb Inflammatory Bowel Disease Trial

  • Crohn's disease and ulcerative colitis
  • Endoscopy video, MR enterography
  • SES-CD and Mayo Endoscopic Score

Challenge

In inflammatory bowel disease trials, endoscopic and cross-sectional assessments of disease activity are inherently interpretive. When scoring is performed at individual sites, that subjectivity translates directly into variability: the same endoscopic finding may be scored differently by different investigators, and eligibility decisions can diverge accordingly. The sponsor needed to reduce this inconsistency from both the screening process and the SES-CD and Mayo Endoscopic Score assessments that anchored the trial's efficacy evaluations.

Read the case study
Intrinsic Imaging

Ophthalmology

Geographic Atrophy and Neovascular AMD Trial

  • SD-OCT, fundus autofluorescence
  • Lesion area measurement
  • Multi-reader consensus

Challenge

The trial's efficacy assessments depended on precise central measurement of geographic atrophy lesion area and consistent longitudinal tracking of choroidal neovascularization. Lesion boundaries in retinal imaging are frequently indistinct, and small differences in how those boundaries are delineated translate into meaningful differences in measured area—differences large enough to confound endpoint analysis when measurements are compared across timepoints and readers.

Read the case study
Intrinsic Imaging

Oncology

Fast-Track Rare Disease Oncology Trial

  • 40 sites in 14 countries
  • Fewer than 3 patients per site
  • Priority Review program

Challenge

Registration trials in rare diseases face substantial recruitment and operational constraints. With fewer than three patients per site spread across 40 sites in 14 countries, each imaging timepoint contributed materially to the limited dataset, and any delay in central review directly threatened enrollment momentum. The sponsor's expedited development and submission schedule required rapid core lab activation and responsive query resolution without compromising the methodological rigor or documentation of imaging assessments.

Read the case study
Intrinsic Imaging

Central Nervous System

Mid-Study Transfer of a Phase III MS MRI

  • 80 sites
  • Brain MRI
  • Gd-enhancing and new T2 lesions

Challenge

A Phase III multiple sclerosis program experienced persistent central review deficiencies under its previous core lab. Lesion assessments demonstrated weak inter-reader agreement, calling into question the reliability of the gadolinium-enhancing and new T2 lesion counts on which the trial's endpoints depended. Compounding the problem, more than 1,800 MRI examinations awaited central review, and the backlog continued to grow. The sponsor needed to transfer the program mid-study while preserving interpretive continuity with the assessments already completed.

Read the case study
Intrinsic Imaging

Medical Device

Rescuing a Stalled Peripheral Vascular Trial

  • 35 sites
  • Duplex ultrasound, angiography
  • Patency and restenosis

Challenge

A peripheral vascular medical device trial encountered substantial delays attributable to inadequate imaging quality. Substandard duplex ultrasound submissions and incomplete angiographic series had rendered nearly a quarter of follow-up timepoints unevaluable, placing the longitudinal patency and restenosis dataset—and with it the trial's 12-month endpoint—at substantial risk. Restoring endpoint evaluability required correction of site acquisition practices in addition to improvements in central interpretation and submission review.

Read the case study
Intrinsic Imaging

Oncology

Lymphoma Trial Using Lugano Classification

  • 45 sites
  • FDG PET/CT
  • Lugano 2014 and Deauville scoring

Challenge

In lymphoma trials, treatment decisions and endpoint determinations rest on metabolic response classification, yet Deauville scoring can vary materially when performed independently at individual sites. Wide divergence in site-level scoring had made complete metabolic response classifications difficult to trust, threatening the integrity of the trial's response-based endpoints and complicating the planned interim analysis. The sponsor required a central review process that could standardize interpretive conventions and document the resolution of discordant assessments.

Read the case study
Intrinsic Imaging

Oncology

Glioblastoma Trial With RANO Criteria

  • 30 sites
  • Brain MRI with perfusion
  • RANO and mRANO

Challenge

Following chemoradiation, glioblastoma patients frequently exhibit treatment-related imaging changes that mimic tumor progression. Distinguishing pseudoprogression from true progression is among the most difficult judgments in neuro-oncology imaging, and premature or inconsistent progression determinations can distort progression-free survival analyses and lead to inappropriate treatment changes. The trial required central application of RANO and modified RANO criteria rigorous enough to manage this ambiguity uniformly across all 30 sites.

Read the case study
Intrinsic Imaging

Oncology

Metastatic Prostate Cancer With PCWG3 Review

  • 65 sites
  • Bone scintigraphy, CT
  • PCWG3 and RECIST 1.1

Challenge

Assessment of radiographic progression-free survival in metastatic prostate cancer requires consistent application of PCWG3 bone progression conventions, including the 2+2 rule and its specified lesion-count and confirmatory imaging requirements. Across 65 sites, this rule was being applied inconsistently, with the flare phenomenon and unconfirmed lesions variously counted or disregarded. Such inconsistency threatened the reliability of the rPFS endpoint and the reproducibility of progression event dating across the trial.

Read the case study
Intrinsic Imaging

Oncology

Hepatocellular Carcinoma Trial Using mRECIST

  • 50 sites in 12 countries
  • Multiphase CT, MRI
  • mRECIST and LI-RADS

Challenge

Assessment of hepatocellular carcinoma under mRECIST relies on measuring viable, arterially enhancing tumor rather than overall lesion size, making appropriate arterial-phase timing essential for reliable measurement. Across 50 sites in 12 countries, variation in multiphase acquisition timing had compromised the reliability of viable tumor measurements, since a poorly timed arterial phase can render enhancement unassessable. The trial's response-based endpoints required that every examination capture the contrast phases necessary for valid mRECIST assessment.

Read the case study
Intrinsic Imaging

AI/CAD

Ground Truth for a Breast Cancer Detection AI

  • Digital mammography, tomosynthesis
  • Lesion-level annotation
  • Pathology-confirmed truth

Challenge

An AI developer required a large, independent test dataset to support a standalone performance study of a breast cancer detection algorithm. The evidentiary requirements for such studies are substantial: the reference standard must be established independently of the algorithm, truth determinations must be defensible at the lesion level, and the dataset must remain independently sequestered from any use in algorithm training. Assembling thousands of cases meeting these criteria demanded both scale and methodological discipline.

Read the case study
Intrinsic Imaging

AI/CAD

Chest CT Lung Nodule MRMC Reader Study

  • Low-dose chest CT
  • 18 readers
  • Aided and unaided reads

Challenge

Evaluating the effect of a lung nodule detection tool on reader performance required a multi-reader multi-case study comparing reader performance with and without algorithmic assistance. The design demanded readers spanning a range of experience levels to support generalizable conclusions, together with a reading workflow that would prevent recall of prior interpretations from contaminating the comparison between aided and unaided sessions. Every element of the design had to satisfy the evidentiary expectations of a 510(k) submission.

Read the case study
Intrinsic Imaging

Medical Device

Spinal Fusion Device Trial With Fusion Review

  • 28 sites
  • CT, flexion-extension radiographs
  • 24-month fusion endpoint

Challenge

Evaluating the effectiveness of a spinal fusion medical device requires reproducible imaging evidence of fusion and implant stability across longitudinal follow-up. Fusion status and subsidence had to be assessed consistently across 24 months of post-surgical follow-up, with measurements sufficiently reproducible to support the trial's fusion endpoint. Given the well-documented subjectivity of radiographic fusion assessment, the sponsor needed a central methodology that could withstand scrutiny in an IDE final report.

Read the case study
Intrinsic Imaging

Central Nervous System

Parkinson's Trial With DaT-SPECT Imaging

  • 40 sites
  • DaT-SPECT, 3T MRI
  • Striatal binding ratios

Challenge

Quantitative striatal binding ratios derived from DaT-SPECT imaging served both as an enrollment screening tool and as a longitudinal biomarker in this Parkinson's disease trial. However, differences in imaging systems and reconstruction practices across 40 sites introduced variability into the measurements used for screening and longitudinal assessment. Without harmonization, apparent differences in binding ratios risked reflecting scanner characteristics rather than underlying biology, undermining both screening accuracy and biomarker reliability.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

Heart Failure Trial Echocardiography Core Lab

  • 75 sites
  • Transthoracic echocardiography
  • LVEF, GLS and LV volumes

Challenge

In heart failure trials, ejection fraction and myocardial strain measurements frequently determine both eligibility and efficacy, yet echocardiography is among the most operator-dependent of imaging modalities. Across 75 sites, differences in image acquisition quality and measurement technique placed the LVEF, global longitudinal strain, and ventricular volume endpoints at risk. The sponsor required central assessment capable of delivering consistent, reproducible quantification from imaging acquired under real-world site conditions.

Read the case study
Intrinsic Imaging

Musculoskeletal

Rheumatoid Arthritis Modified Sharp Scoring

  • 60 sites
  • Hand and foot radiographs
  • mTSS erosion and JSN

Challenge

Structural progression in rheumatoid arthritis is measured in small increments of erosion and joint space narrowing, and detecting change over 52 weeks demands a scoring methodology of exceptional repeatability. Modified total Sharp scoring is labor-intensive and interpretive, and without rigorous central control, reader drift and inter-reader variability can easily exceed the magnitude of the treatment effect the trial seeks to demonstrate. The sponsor needed central assessment disciplined enough to report the smallest detectable change with confidence.

Read the case study
Intrinsic Imaging

Gastroenterology & Metabolic

NASH Trial With MRI-PDFF and Liver Stiffness

  • 50 sites
  • MRI-PDFF, MR elastography
  • Liver fat and stiffness

Challenge

Quantitative liver imaging biomarkers are only as reliable as the scanners that produce them. In this NASH program, vendor differences in MRI-PDFF and MR elastography implementation threatened the comparability of liver fat fraction and stiffness measurements across 50 sites. Since these quantitative endpoints would inform Phase IIb dose selection, even modest cross-vendor bias could influence the interpretation of biomarker differences relevant to subsequent development.

Read the case study
Intrinsic Imaging

Ophthalmology

Diabetic Macular Edema Trial OCT Endpoints

  • 70 sites
  • SD-OCT, fluorescein angiography
  • Central subfield thickness

Challenge

Central subfield thickness measured by OCT anchored this diabetic macular edema trial's primary endpoint, yet automated retinal layer segmentation can introduce platform-dependent boundary errors that compromise measurement reliability. With 70 sites using multiple OCT platforms, uncorrected segmentation errors threatened the comparability of thickness measurements on which the efficacy analysis depended.

Read the case study
Intrinsic Imaging

Oncology

Rapid Pediatric Neuroblastoma Trial Startup

  • 25 sites in 9 countries
  • MIBG scintigraphy, CT, MRI
  • Curie score and INRC

Challenge

Pediatric oncology trials often enroll small, geographically dispersed populations, making timely study activation and screening assessment important operational priorities. The sponsor required central review capability—encompassing MIBG scintigraphy, CT, and MRI with Curie scoring and INRC response assessment—to be fully operational within weeks, across 25 sites in 9 countries. Eligibility determinations had to be returned promptly so that central imaging review could support enrollment decisions within the required timelines.

Read the case study
Intrinsic Imaging

Gastroenterology & Metabolic

Obesity Trial With DXA Body Composition and MRI Fat Quantification

  • 90 sites in 14 countries
  • DXA, abdominal MRI, MRI-PDFF
  • Lean mass, visceral fat and liver fat

Challenge

Weight loss alone no longer satisfies regulators, payers or clinicians evaluating an incretin-based obesity therapy. The sponsor of this Phase III program needed to show not only how much weight participants lost but what that weight consisted of: whether fat mass fell while lean mass was preserved, and whether visceral adipose tissue and liver fat, the depots most closely tied to cardiometabolic risk, changed in parallel. Those questions placed dual-energy X-ray absorptiometry and quantitative MRI at the center of the trial's key secondary endpoints.

Read the case study
Intrinsic Imaging

Oncology

Imaging Core Lab Support Through NDA Submission and FDA Inspection

  • 55 sites
  • CT, MRI
  • RECIST 1.1 BICR and FDA inspection

Challenge

Progression-free survival by blinded independent central review was the primary endpoint of this Phase III solid tumor trial, which meant that the imaging core lab's work would be examined by the FDA as closely as the sponsor's own clinical data. The sponsor planned to file a New Drug Application within months of database lock and expected both information requests during review and a pre-approval inspection of the imaging vendor.

Read the case study
Intrinsic Imaging

Oncology

Multiple Myeloma Trial With IMWG Imaging Criteria

  • 120 sites in 22 countries
  • Whole-body low-dose CT, FDG PET/CT, MRI
  • IMWG response and extramedullary disease

Challenge

Response in multiple myeloma is defined largely by laboratory measures, which can lead sponsors to underestimate the imaging work a global trial requires. In this Phase III study the imaging component was decisive in three places: documenting bone disease and extramedullary plasmacytomas at baseline, confirming progression when new bone lesions or soft-tissue masses appeared, and assessing metabolic response on FDG PET/CT in the subset of patients with imaging-evaluable disease.

Read the case study
Intrinsic Imaging

Central Nervous System

ARIA Safety Monitoring in an Anti-Amyloid Alzheimer's Trial

  • 110 sites
  • 3T MRI with FLAIR and T2*-GRE/SWI
  • ARIA-E and ARIA-H severity grading

Challenge

Amyloid-related imaging abnormalities are the defining safety signal of anti-amyloid antibody therapy. ARIA with edema or effusion and ARIA with hemosiderin deposition are usually asymptomatic but can be serious, and dosing decisions at each visit depend on knowing whether they are present and how severe they are. In this Phase III trial, protocol-specified safety MRI scans were scheduled before selected infusions, and the investigator could not proceed with dosing until the central read was available.

Read the case study
Intrinsic Imaging

Oncology

Radioligand Therapy Trial With PSMA PET Eligibility and Dosimetry

  • 60 sites
  • PSMA PET/CT, post-therapy SPECT/CT, CT and bone scan
  • Eligibility reads, PCWG3 and dosimetry

Challenge

Radioligand therapy ties patient selection to imaging more tightly than almost any other treatment class. In this Phase III trial of a PSMA-targeted radiopharmaceutical in metastatic castration-resistant prostate cancer, a participant could be randomized only if central review confirmed PSMA-positive disease on PET/CT and the absence of PSMA-negative measurable lesions. Randomization windows were short, so eligibility reads had to be returned quickly and consistently to 60 sites, several of which used different PSMA PET tracers with different normal biodistribution.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

Idiopathic Pulmonary Fibrosis Trial With Quantitative HRCT

  • 45 sites
  • Thin-section non-contrast HRCT
  • UIP pattern confirmation and quantitative fibrosis score

Challenge

Forced vital capacity remains the accepted primary endpoint in idiopathic pulmonary fibrosis, but it is noisy, effort-dependent and slow to show treatment effect. The sponsor of this Phase IIb/III program wanted imaging to do two jobs: confirm at screening that each participant's high-resolution CT showed a usual interstitial pneumonia pattern consistent with the diagnosis, and quantify the extent of fibrotic lung over 52 weeks as a key secondary endpoint that could support the FVC result.

Read the case study
Intrinsic Imaging

Oncology

Phase I/IIa Imaging Endpoint Strategy for a Biotech Go/No-Go Decision

  • 12 sites
  • FDG PET/CT, contrast CT
  • RECIST 1.1, PERCIST and CT volumetrics

Challenge

An emerging biotechnology company was taking its first oncology asset into a Phase I/IIa study and had a single decision to make at the end of dose escalation: whether to open an expansion cohort, a step that would commit most of its remaining capital. The company's board wanted evidence of biological activity by week 8 of treatment in the recommended-dose cohort. Conventional RECIST 1.1 response at that timepoint would almost certainly be stable disease in most patients, which answers nothing.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

Imaging Data Transfer and Query Resolution Integrated With Sponsor EDC

  • 140 sites
  • Echocardiography, cardiac CT
  • EDC-integrated transfers and query management

Challenge

In a large cardiovascular outcomes trial, imaging is one data stream among many, and its value depends on how cleanly it joins the rest. This 140-site study collected echocardiography at four visits and cardiac CT in a sub-study, and the sponsor's data management team had to reconcile every central imaging result with the visit record in its electronic data capture system before each data safety monitoring board meeting and interim analysis.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

Rare Disease Cardiomyopathy Trial With Echo and Cardiac MRI

  • 80 sites in 16 countries
  • Echocardiography, cardiac MRI
  • LVOT gradient, wall thickness and LVEF

Challenge

Obstructive hypertrophic cardiomyopathy is a rare disease in which the imaging measurements are the endpoints. In this Phase III trial, the primary efficacy measure was the change in left ventricular outflow tract gradient at rest and with Valsalva provocation, assessed by echocardiography, and cardiac MRI quantified left ventricular mass and maximal wall thickness in a sub-study. At the same time, the mechanism of the investigational drug carried a known risk of reducing systolic function, so the protocol required that any left ventricular ejection fraction below a defined threshold be reported promptly to guide dose adjustment.

Read the case study
Intrinsic Imaging

Gastroenterology & Metabolic

ADPKD Trial With Total Kidney Volume MRI

  • 50 sites
  • Non-contrast T2-weighted MRI
  • Height-adjusted total kidney volume and Mayo imaging class

Challenge

Autosomal dominant polycystic kidney disease progresses slowly, and kidney function can remain normal for years while the kidneys enlarge. Total kidney volume has been qualified by regulators as a prognostic enrichment biomarker precisely because it identifies the patients most likely to decline during a trial. In this Phase III program, height-adjusted total kidney volume on MRI served two purposes: to classify each candidate at screening into the Mayo imaging class that determined eligibility, and to measure the rate of kidney growth over 24 months as a key secondary endpoint.

Read the case study
Intrinsic Imaging

Medical Device

Cervical Disc Replacement IDE Trial With Range-of-Motion Analysis

  • 25 sites
  • Flexion-extension radiographs, CT
  • Range of motion, heterotopic ossification and adjacent segments

Challenge

A cervical total disc replacement is intended to do what a fusion cannot: preserve motion at the treated level. The pivotal IDE trial for this device therefore had to demonstrate two things on imaging, that the implant maintained a functional range of motion through 24 months and that it did not produce the complications that can defeat that purpose, chiefly heterotopic ossification that bridges and immobilizes the segment, device migration or subsidence, and accelerated degeneration at the adjacent levels. The device was being compared with anterior cervical discectomy and fusion, so the control arm required fusion assessment as well.

Read the case study
Intrinsic Imaging

AI/CAD

Pivotal MRMC Study of CAD Software With 14,400 Reviews With and Without CAD

  • 14,400+ reviews with and without CAD
  • Multi-reader multi-case
  • Reader performance change with CAD

Challenge

A pivotal multi-reader multi-case study was required to assess the clinical performance of computer-aided detection software, with more than 14,400 reviews to be performed without CAD and then with CAD. The sponsor's claim depended on demonstrating that readers detected more true findings with CAD without an unacceptable increase in false positives, which requires precise control over how and when readers see CAD marks.

Read the case study
Intrinsic Imaging

AI/CAD

Tenth MRMC Trial for CAD, AI and Deep Learning Software

  • 15 to 30 readers sourced from a 200+ network
  • Multi-reader multi-case
  • FDA submission support

Challenge

A developer of CAD, AI and deep-learning software required an MRMC study in support of an FDA submission, and needed the reader panel recruited, qualified and reading within weeks of contract. Reader recruitment is the most common cause of MRMC schedule slippage: panels of 15 to 30 readers must be board certified, representative of intended users, free of conflicts and prior exposure to the software, and available for multiple reading sessions separated by a washout period.

Read the case study
Intrinsic Imaging

AI/CAD

Pivotal MRMC Trial of AI Software Detecting Musculoskeletal Pathology

  • Musculoskeletal radiographs
  • Multi-reader multi-case
  • Lesion-level detection with localization

Challenge

An emerging AI company developing software to detect musculoskeletal pathology on radiographs required a pivotal clinical trial to support FDA and European submissions. Musculoskeletal findings such as fractures are often subtle, multiple and anatomically distributed, so the study had to score detection at the finding level with localization, not simply at the image level, and the reference standard had to establish the location of every true finding.

Read the case study
Intrinsic Imaging

AI/CAD

Pivotal Device Trial of AI Software for Screening Clinical Images

  • Standalone and MRMC performance
  • Enriched screening case set
  • Sensitivity, specificity and reader AUC

Challenge

An emerging AI company required a pivotal medical device trial to assess the clinical performance of software that screens clinical images for findings requiring attention. Screening populations have low disease prevalence, so a case set drawn at random would contain too few positives to estimate sensitivity with any precision, while an over-enriched set would misrepresent the specificity readers achieve in practice.

Read the case study
Intrinsic Imaging

AI/CAD

Pivotal MRMC Trial of AI Detection Software With 14,000 Radiology Reviews

  • 14,000+ reader reviews
  • Fully crossed multi-reader multi-case
  • Reader AUC with and without AI

Challenge

A leading artificial intelligence company needed a pivotal multi-reader multi-case study to support its FDA submission for software that detects pathology on medical images. The study design called for more than 14,000 individual radiology reviews, each reader interpreting every case both with and without AI assistance, within a timeline set by the sponsor's submission plan.

Read the case study
Intrinsic Imaging

Oncology

Five-Year Multicenter Metastatic Colorectal Cancer Trial Across 40 Sites

  • 40+ sites, hundreds of patients
  • Contrast CT, MRI
  • RECIST

Challenge

A five-year multicenter clinical trial of a treatment for metastatic colorectal cancer enrolled hundreds of patients at more than 40 investigator sites. The length of the trial and the volume of imaging created operational risk: sites changing scanners and staff, image transfer delays accumulating over years, and the potential for reader drift across a long program.

Read the case study
Intrinsic Imaging

Oncology

Four-Year Multinational Phase II Metastatic Breast Cancer Trial Across 60 Sites

  • 60+ sites in 10 countries
  • CT, MRI, bone scan
  • RECIST

Challenge

A four-year multinational Phase II trial in metastatic breast cancer spanned more than 60 investigator sites in 10 countries. Over that duration and geography, the sponsor faced the operational risks of inconsistent acquisition, delayed image transfer and variable site interpretation of RECIST, any of which could compromise the response dataset.

Read the case study
Intrinsic Imaging

Oncology

Breast Cancer Trial With 3,000 Multimodality Breast Imaging Reviews

  • ~3,000 reviews
  • Digital mammography, breast ultrasound, breast MRI
  • Lesion detection and BI-RADS assessment

Challenge

A clinical trial evaluating the safety and effectiveness of a new breast cancer product required nearly 3,000 central reviews of breast imaging. Breast imaging assessment is multimodal and interpretive: lesion detection and BI-RADS categorization on mammography, ultrasound and MRI vary between readers, and the product's effectiveness depended on consistent lesion-level assessment across modalities and timepoints.

Read the case study
Intrinsic Imaging

Oncology

Phase II Metastatic Pancreatic Cancer Trial With RECIST and PERCIST

  • Phase II efficacy trial
  • Contrast CT, FDG PET/CT
  • RECIST 1.1 and PERCIST

Challenge

A Phase II efficacy trial of a novel investigational biologic enrolled patients with metastatic pancreatic adenocarcinoma or advanced colorectal cancer refractory to standard therapy. Pancreatic tumors are poorly marginated on CT and respond slowly in size, so the sponsor required metabolic response assessment under PERCIST alongside anatomic RECIST assessment to detect early biologic activity.

Read the case study
Intrinsic Imaging

Oncology

Phase I/II Biologic Trial in Metastatic Colorectal Cancer With Unresectable Liver Metastases

  • Multicenter Phase I/II
  • Contrast CT, liver MRI
  • RECIST 1.1 and liver-specific response

Challenge

A multicenter Phase I/II trial evaluated a novel investigational biologic in patients with unresectable colorectal liver metastases. Early-phase trials generate decisions about dose and expansion from small numbers of patients, so each response assessment carried significant weight, and liver metastases imaged with CT and MRI present measurement challenges from contrast phase, lesion conspicuity and treatment-related changes in lesion appearance.

Read the case study
Intrinsic Imaging

Oncology

Global Hepatocellular Carcinoma Trial With Dynamic Contrast-Enhanced MRI

  • Global trial, Asia-weighted enrollment
  • DCE-MRI
  • mRECIST and perfusion parameters

Challenge

A global clinical trial of a new therapy for hepatocellular carcinoma used dynamic contrast-enhanced MRI to assess tumor response, with heavy enrollment in Asia where HCC incidence is highest. DCE-MRI requires precise contrast timing and multiphase acquisition, and the arterial-phase enhancement on which modified RECIST depends is easily lost with mistimed acquisition or respiratory motion in patients with cirrhosis and ascites.

Read the case study
Intrinsic Imaging

Oncology

International Phase II Non-Hodgkin Lymphoma Trial With PET/CT and PET/MRI

  • International Phase II
  • FDG PET/CT, PET/MRI
  • Lugano classification and Deauville score

Challenge

An international Phase II trial assessed a new treatment for non-Hodgkin lymphoma using FDG PET combined with CT or, at some sites, MRI. Metabolic response assessment under the Lugano classification depends on Deauville scoring relative to mediastinal and liver uptake, which varies with uptake time, glucose level and reconstruction, and the inclusion of PET/MRI alongside PET/CT introduced a second hybrid modality with different attenuation correction and anatomical reference.

Read the case study
Intrinsic Imaging

Oncology

International Phase II Trial in Advanced Squamous Cell Carcinoma

  • 32 sites in 9 countries
  • CT, MRI
  • RECIST 1.1

Challenge

An international Phase II trial evaluated a new treatment for advanced squamous cell carcinoma. Squamous tumors of the head and neck, lung, esophagus and skin present differently and are imaged with different modalities, and the sponsor permitted either CT or MRI depending on site and tumor location, which introduced cross-modality comparison risk into longitudinal response assessment.

Read the case study
Intrinsic Imaging

Oncology

Phase II Glioblastoma Multiforme Trial With Central Neuroradiology Review

  • Phase II
  • Brain MRI
  • RANO response assessment

Challenge

A Phase II trial evaluated a novel treatment for glioblastoma multiforme, the most common and aggressive primary brain tumor in adults. Response assessment in glioblastoma is complicated by pseudoprogression after chemoradiation, by the effect of corticosteroids on enhancement, and by variability in MRI acquisition across sites, all of which can produce apparent progression that is not tumor growth.

Read the case study
Intrinsic Imaging

Oncology

Pivotal Phase III Comparison of an Oral Chemotherapeutic Against the Leading Metastatic Breast Cancer Therapy

  • 5,500+ radiological reads
  • CT, MRI, bone scan
  • RECIST 1.1 BICR

Challenge

This pivotal Phase III trial compared the safety, tolerability and tumor response of a new oral chemotherapeutic against the leading therapy for metastatic breast cancer. Since the comparator was an established standard, the margin the sponsor needed to demonstrate was narrow, and any systematic bias or noise in central tumor assessment could obscure a real difference between arms.

Read the case study
Intrinsic Imaging

Oncology

International Phase III Trial of a Novel Approach to NSCLC Brain Metastases

  • Several thousand reads
  • Brain MRI, body CT
  • Joint oncology and neuroradiology review

Challenge

A global Phase III trial compared a novel approach to treating non-small cell lung cancer brain metastases against standard of care. The trial's efficacy conclusions depended on both intracranial control and systemic disease status, which meant brain MRI and body CT had to be reviewed under different criteria by different subspecialists while producing a single coherent assessment per patient per visit.

Read the case study
Intrinsic Imaging

Oncology

Global Phase III Oral Chemotherapeutic Trial in Metastatic Breast Cancer

  • 110 sites in 20 countries
  • CT, MRI, bone scan
  • RECIST 1.1 BICR

Challenge

A global pivotal Phase III trial of a new oral chemotherapeutic for metastatic breast cancer required blinded independent central review of thousands of radiological examinations. Metastatic breast cancer frequently involves bone, where lesions are non-measurable under RECIST 1.1 and progression judgments depend on consistent interpretation of bone scans and correlative CT or MRI, and across 110 sites in 20 countries acquisition practice varied considerably.

Read the case study
Intrinsic Imaging

Oncology

Phase II Immuno-Oncology Trial in NSCLC and SCLC

  • 45 sites in 8 countries
  • Contrast CT, MRI
  • RECIST 1.1 with immune-response flagging

Challenge

A multi-year Phase II immuno-oncology program enrolled patients with both non-small cell and small cell lung cancer under a single imaging charter. Checkpoint-inhibitor therapy produces atypical response patterns, including transient lesion enlargement and new lesions that later regress, and the sponsor needed RECIST 1.1 applied consistently across two histologies while retaining enough information to interpret suspected pseudoprogression at the program level.

Read the case study
Intrinsic Imaging

Oncology

Phase III NSCLC Brain Metastases Trial With 6,000 Neuroradiology Assessments

  • 6,000+ neuroradiology assessments
  • Contrast-enhanced brain MRI
  • RANO-BM intracranial response

Challenge

An international Phase III trial of a novel treatment for brain metastases from non-small cell lung cancer required more than 6,000 neuroradiology assessments of intracranial response. Brain metastases are small, often numerous, and susceptible to measurement variability from slice thickness, contrast timing and field strength, so small differences in acquisition or reader technique could change response categories and distort the intracranial progression-free survival endpoint.

Read the case study
Intrinsic Imaging

Oncology

GIST Trial With RECIST 1.1 and Choi Criteria

  • 38 sites
  • Contrast-enhanced CT
  • RECIST 1.1 and Choi criteria

Challenge

In gastrointestinal stromal tumors treated with targeted therapy, responding lesions often change density and become cystic or hemorrhagic without shrinking, and may even enlarge. Size-based RECIST 1.1 assessment alone can therefore misclassify responders as stable or progressive disease. The sponsor of this multi-year trial of a novel GIST therapeutic required both RECIST 1.1 and Choi criteria applied in parallel, which demands reproducible Hounsfield-unit density measurements that are highly sensitive to contrast phase and acquisition technique.

Read the case study
Intrinsic Imaging

Medical Device

Neurointerventional Endovascular Device Trial

  • Neurovascular device trial
  • Catheter angiography, CT, MRI
  • Device safety and efficacy

Challenge

A clinical trial of a neurointerventional endovascular device required imaging assessment of safety and efficacy. Neurovascular device endpoints depend on angiographic grading that is sensitive to projection, timing and frame selection, and on cross-sectional imaging to detect hemorrhage, infarction and other procedural complications, with substantial variation in how sites acquire and archive angiographic runs.

Read the case study
Intrinsic Imaging

Medical Device

International Phase III Orthopedic Device Trial With 7,000 Imaging Examinations

  • 400+ patients, ~7,000 examinations
  • CT, MRI, radiographs
  • Quantitative and qualitative orthopedic assessment

Challenge

An international Phase III trial of a novel orthopedic device enrolled more than 400 patients and generated approximately 7,000 CT, MRI and radiographic examinations for the assessment of device safety and effectiveness. Orthopedic device endpoints combine quantitative measurements such as alignment, migration and implant position with qualitative assessments of bone response, loosening and adjacent-segment change, each requiring consistent technique across modalities and timepoints.

Read the case study
Intrinsic Imaging

Medical Device

Multi-Center Study of a Novel Vascular Device

  • Multi-center device study
  • Angiography, CT angiography, duplex ultrasound
  • Deployment success and surveillance

Challenge

A multi-center study of a novel vascular device required imaging assessment of deployment, device position and vessel response over follow-up. Vascular device surveillance combines angiographic measurements at the procedure with CT angiography and duplex ultrasound thereafter, and each modality measures vessel dimensions differently, which can produce apparent changes that reflect modality rather than device performance.

Read the case study
Intrinsic Imaging

Medical Device

Clinical Study of a Novel Neurointerventional Device

  • Neurovascular device study
  • Catheter angiography, CT, MRI
  • Angiographic outcome and procedural safety

Challenge

A clinical study of a novel neurointerventional device required central review of catheter angiography and cross-sectional imaging to assess technical success, angiographic outcome and procedural complications. Neurovascular imaging endpoints such as recanalization grade, aneurysm occlusion class and vessel injury depend on frame selection, projection and timing within angiographic runs, and are among the most reader-dependent assessments in device trials.

Read the case study
Intrinsic Imaging

Medical Device

Four-Year Venous Stent Trial for Symptomatic Venous Outflow Obstruction

  • 4,000+ venogram, x-ray and ultrasound exams
  • Venography, duplex ultrasound, radiographs
  • Primary patency and stent integrity

Challenge

A four-year clinical trial of an interventional device for symptomatic venous outflow obstruction required radiological review of more than 4,000 venograms, radiographs and ultrasound examinations. Venous patency assessment combines duplex ultrasound flow and diameter measurements with venographic stenosis grading, and the two modalities can disagree; stent integrity and migration must be assessed on radiographs against a post-deployment baseline.

Read the case study
Intrinsic Imaging

Medical Device

International Trial of a Medical Device for the Treatment of Lung Cancer

  • International device trial
  • Contrast chest CT, PET/CT
  • Local control and device-related change

Challenge

An international clinical trial evaluated a medical device designed to treat lung cancer. Device-based tumor treatment produces local tissue changes, including consolidation, cavitation and fibrosis, that evolve over months and can be confused with residual or recurrent tumor on both CT and PET. Response assessment therefore required criteria adapted to a local therapy rather than conventional systemic RECIST alone.

Read the case study
Intrinsic Imaging

Medical Device

Genitourinary Device Trial With Dynamic Pelvic Floor MRI

  • Urinary incontinence device
  • Dynamic pelvic floor MRI
  • Device position and pelvic floor mobility

Challenge

A medical device trial for the treatment of urinary incontinence used dynamic MRI of the pelvic floor to assess device position and its effect on bladder neck and urethral mobility. Dynamic pelvic MRI is highly operator-dependent: patient coaching, straining effort and acquisition timing all affect the measured displacement, and few sites had routine experience with the technique.

Read the case study
Intrinsic Imaging

Medical Device

International Phase II Study of a Novel Vascular Device

  • International Phase II device study
  • Angiography, duplex ultrasound, CT angiography
  • Patency and device integrity

Challenge

An international Phase II study evaluated a novel vascular medical device, with imaging endpoints covering deployment success, patency and device integrity over follow-up. Sites across several countries used different combinations of procedural angiography, duplex ultrasound and CT angiography, and duplex technique in particular varies widely between vascular laboratories.

Read the case study
Intrinsic Imaging

Medical Device

Interventional Device Trial for Prevention of Pulmonary Emboli

  • Vena cava filter class device
  • CT venography, fluoroscopy, radiographs
  • Device position, integrity and caval patency

Challenge

A trial of a novel interventional device for the prevention of pulmonary emboli required imaging assessment of device placement, migration, tilt, fracture, caval penetration and thrombus over an extended follow-up. These safety endpoints rely on precise comparison of serial imaging against the immediate post-deployment baseline, and the sponsor's sites used a mix of fluoroscopy, radiographs and CT venography.

Read the case study
Intrinsic Imaging

Medical Device

Interventional Device Trial for Percutaneous Tumor Ablation

  • Interventional oncology device
  • Contrast CT, MRI, ultrasound
  • Ablation zone and local tumor progression

Challenge

A developer of a percutaneous tumor ablation device required imaging evidence of technical success and durable local tumor control for primary and metastatic tumors. Assessment of ablation zones is multimodal and time-dependent: the zone evolves over months, benign periablational enhancement can mimic residual tumor, and the margins that predict local recurrence must be measured in three dimensions against the pre-procedure tumor.

Read the case study
Intrinsic Imaging

Medical Device

International Class III Device Trial for Lower Back Pain

  • Large international Class III device trial
  • Lumbar radiographs, CT, MRI
  • Device position, disc height and adjacent segments

Challenge

A large international clinical trial investigated the efficacy of a Class III medical device for the treatment of lower back pain. Spinal device trials combine quantitative radiographic measurement of disc height, segmental alignment and device position with CT assessment of bony response and MRI assessment of adjacent-segment and soft-tissue change, and metal artifact degrades both CT and MRI around the implant.

Read the case study
Intrinsic Imaging

Medical Device

Validation Study of a Gastrointestinal Motility Device With a Radiation-Sparing Protocol

  • Device validation study
  • Abdominal radiography, low-dose CT
  • Transit and motility endpoints

Challenge

A developer of an innovative device for evaluating gastrointestinal motility required a validation study comparing the device's output against an imaging reference standard. Conventional transit studies rely on serial radiographs or fluoroscopy, and a schedule dense enough to validate the device could expose healthy volunteers and patients to meaningful cumulative radiation.

Read the case study
Intrinsic Imaging

Medical Device

Phase II Evaluation of a Novel Tumor Imaging Platform

  • Diagnostic device trial
  • Novel imaging platform vs reference standard
  • Sensitivity and specificity endpoints

Challenge

A medical device developer sought Phase II evidence that its novel imaging platform could help physicians distinguish malignant from non-malignant tissue across several tumor types. Unlike a therapeutic trial, the endpoint was diagnostic performance, which meant every case needed a reliable reference standard, and the novel images had to be evaluated by readers under conditions that neither overstated nor understated the device's contribution.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

Cardiovascular Clinical Trial With 1,500 Multimodality Reviews

  • 1,500 radiological reviews
  • Echocardiography, cardiac MRI, CT
  • Safety and effectiveness endpoints

Challenge

A cardiovascular clinical trial required 1,500 central reviews to evaluate the clinical safety and effectiveness of a new product. Cardiovascular endpoints span modalities, and the trial collected echocardiography, cardiac MRI and CT at different timepoints, each with its own acquisition variability and measurement conventions for cardiac function and structure.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

International Phase III Cystic Fibrosis Trial With Structured Chest CT Scoring

  • International multicenter Phase III
  • Chest CT, chest radiography
  • Bronchiectasis, mucus plugging and air trapping scores

Challenge

An international Phase III trial of an investigational drug for cystic fibrosis used chest imaging to assess the treatment's effect on lung pathophysiology. Structured CT scoring of bronchiectasis, mucus plugging, peribronchial thickening, parenchymal opacity and hyperinflation is reader-intensive and subjective, and in a population that includes children, radiation dose and breath-hold capability constrain acquisition.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

International Phase II Cardiac Safety Trial With Cardiac MRI

  • 30 sites in 7 countries
  • Cardiac MRI
  • LVEF, LV volumes and mass

Challenge

An international Phase II trial required cardiac MRI to assess the cardiac safety and tolerability of a novel drug. The endpoint depended on detecting small changes in left ventricular ejection fraction, volumes and mass over the treatment period, measurements that vary with scanner vendor, sequence parameters, slice planning and contouring convention.

Read the case study
Intrinsic Imaging

Central Nervous System

Pivotal Multi-Center Acute Ischemic Stroke Trial

  • Pivotal multi-center trial
  • Non-contrast CT, CT angiography, MRI
  • Infarct volume, hemorrhagic transformation, recanalization

Challenge

A pivotal multi-center trial evaluated a new treatment for acute ischemic stroke. Stroke imaging is acquired under extreme time pressure on whatever scanner is available, and the efficacy and safety endpoints depend on neuroradiological assessment of infarct extent, hemorrhagic transformation and vessel status, assessments that vary considerably between readers without a shared framework.

Read the case study
Intrinsic Imaging

Central Nervous System

International Phase III Severe Traumatic Brain Injury Trial Across 100+ Sites

  • 1,000+ patients at 100+ sites
  • Head CT, brain MRI
  • Intracranial pathology progression

Challenge

A large international Phase III trial of a treatment for severe traumatic brain injury enrolled more than 1,000 patients across more than 100 investigator sites. Imaging was acquired in emergency settings on whatever scanner was available, often at night, and the endpoint depended on neuroradiological assessment of the progression of intracranial pathology including contusion expansion, hematoma volume, edema and midline shift.

Read the case study
Intrinsic Imaging

Gastroenterology & Metabolic

Five-Year International Phase II Iron Overload Trial With 4,500 MRI Scans

  • 4,500+ MRI scans over five years
  • Liver and cardiac T2* MRI
  • Liver iron concentration and myocardial T2*

Challenge

A large five-year international Phase II trial of a new therapy for chronic iron overload in transfusion-dependent and hereditary populations involved more than 4,500 MRI examinations for liver and cardiac iron quantification. Over five years, scanner upgrades, software changes and staff turnover at sites threaten the stability of quantitative T2* measurement, and drift of even a few percent would be comparable to the treatment effect being measured.

Read the case study
Intrinsic Imaging

Gastroenterology & Metabolic

Three-Year International Phase II Trial in Chronic Iron Overload

  • Sites in Asia, Europe, North America and the Middle East
  • Liver and cardiac T2* MRI
  • Liver iron concentration and myocardial T2*

Challenge

A three-year international Phase II trial evaluated a new therapy for chronic iron overload using MRI measurement of liver and myocardial iron. T2* relaxometry is quantitative but vendor- and sequence-dependent, and the participating sites spanned Asia, Europe, North America and the Middle East with a wide range of scanner platforms and relaxometry experience.

Read the case study
Intrinsic Imaging

Musculoskeletal

Global Phase II Arthritis Trial With Quantitative Joint Imaging

  • Global Phase II
  • Hand and foot radiographs, joint MRI
  • Structural progression scoring

Challenge

A global Phase II trial investigated the safety and efficacy of a new pharmaceutical compound for arthritis, with imaging endpoints measuring structural progression in affected joints. Radiographic scoring of erosion and joint space narrowing and MRI assessment of synovitis, bone marrow edema and erosion are reader-intensive, semi-quantitative and sensitive to positioning and acquisition technique.

Read the case study
Intrinsic Imaging

Musculoskeletal

Pivotal Phase II Biologic Trial in a Rare Degenerative Neuromuscular Disorder

  • 22 sites in 6 countries
  • Quantitative muscle MRI, DXA
  • Fat fraction and lean mass endpoints

Challenge

A pivotal Phase II trial of a novel biologic for a rare degenerative neuromuscular disorder relied on imaging biomarkers of muscle composition as key efficacy measures. Quantitative muscle MRI fat fraction and DXA lean mass are sensitive to scanner vendor, sequence implementation and positioning, and in a rare disease with small per-site enrollment, every patient's longitudinal data carried disproportionate weight.

Read the case study
Intrinsic Imaging

Cardiovascular & Thoracic

International Phase III Heart Failure Trial With Central CPET Analysis

  • 48 sites in 11 countries
  • Cardiopulmonary exercise testing (CPET)
  • Peak VO2, VE/VCO2 slope, ventilatory threshold

Challenge

An international Phase III trial in heart failure with preserved ejection fraction used change in peak oxygen uptake (peak VO2) from baseline to week 24 as its primary endpoint, with the VE/VCO2 slope and oxygen uptake at the ventilatory threshold as key secondary endpoints. Testing took place at 48 sites in 11 countries using metabolic carts from five manufacturers and both treadmill and cycle ergometers.

Read the case study

Frequently Asked Questions

How should sponsors use Intrinsic Imaging’s Guidance to plan a current study?
Intrinsic Imaging’s Imaging Guidance for Sponsors provides scientific context for selecting imaging methods, response criteria and acquisition controls. Articles describing the evolution of RECIST, iRECIST, Lugano and treatment-specific frameworks help sponsors understand why the assessment approach must fit the disease and therapeutic mechanism. Historical publications should be considered alongside current evidence and the planned study’s objectives, with the applicable criteria and review procedures defined prospectively in the protocol and imaging charter.
Who approves the imaging charter?
The sponsor approves the imaging charter after Intrinsic Imaging’s physicians and operations team have reviewed it. Intrinsic Imaging incorporates comments from the sponsor’s clinical, statistical, and regulatory teams during drafting, so that the signed imaging charter reflects a single method accepted by all parties.
Does Intrinsic Imaging support functional endpoints?
Yes. Intrinsic Imaging supports functional endpoints, including BCVA, visual fields, ERG, full-field stimulus testing and IOP.
Go to more Frequently Asked Questions